In a phase Ib trial, led by Naval Daver and Michael Andreeff at MD Anderson Cancer Center, researchers evaluated the combination of Venclexta (venetoclax) and idasanutlin in 56 patients with R/R AML who were unfit for chemotherapy. IDH1/2 and RUNX1 mutations were associated with higher composite complete remission rates of 50% and 45%, respectively, and were linked to therapy sensitivity.
The world of cancer treatments continues to evolve, and for those diagnosed with blood cancers, a new option can be found in menin inhibitors—the latest form of targeted therapy in advanced acute leukemia.
